Pink Sheet Podcast: House User Fee Bill, Push For OTC Naloxone, SCOTUS Overturning Roe v. Wade
Pink Sheet reporter and editors and HBW Insight editor discuss FDA reforms in the new user fee reauthorization bill, additional industry inducements to market OTC naloxone, and the impact of a Supreme Court’s potential overturning of Roe v. Wade on the agency.
You may also be interested in...
Pink Sheet reporter and editors discuss CDC advisors’ views on COVID-19 vaccine booster policy, new FDA guidance to promote clinical trial diversity, and what some FDA employees are finding when they return to the White Oak headquarters.
Pink Sheet reporters and editors discuss changes to the standard for some COVID-19 treatment emergency use authorizations, late-coming COVID-19 vaccines and their potential effect on the market, and an upcoming HHS biosimilar use and cost study.